|
An observational multicenter French study on unanswered questions in patients with advanced renal cell carcinoma (aRCC) treated with cabozantinib: OCTOPUS. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; BMS; Ipsen; janssen; Pfizer; Sanofi |
|
|
Honoraria - Astellas Pharma; Bayer |
Consulting or Advisory Role - Astellas Pharma; Bayer |
Travel, Accommodations, Expenses - Bayer |
|
|
Honoraria - Bristol-Myers Squibb; Fujifilm; Intuitive Surgical; IPSEN,; MSD |
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - IPSEN, |
|
|
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer |